PPGNZ Stock Overview
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PPGNZ from our risk checks.
My Notes
Capture your thoughts, links and company narrative
PolyPeptide Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 28.93 |
| 52 Week High | CHF 35.73 |
| 52 Week Low | CHF 14.11 |
| Beta | 1.12 |
| 1 Month Change | 1.49% |
| 3 Month Change | -9.47% |
| 1 Year Change | 64.53% |
| 3 Year Change | -78.89% |
| 5 Year Change | n/a |
| Change since IPO | -66.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| PPGNZ | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 1.7% | -7.2% | 0.8% |
| 1Y | 64.5% | -32.8% | 2.7% |
Return vs Industry: PPGNZ exceeded the UK Life Sciences industry which returned -30% over the past year.
Return vs Market: PPGNZ exceeded the UK Market which returned 2.7% over the past year.
Price Volatility
| PPGNZ volatility | |
|---|---|
| PPGNZ Average Weekly Movement | 6.4% |
| Life Sciences Industry Average Movement | 7.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: PPGNZ has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: PPGNZ's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 1,277 | Juan Gonzalez | www.polypeptide.com |
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications.
PolyPeptide Group AG Fundamentals Summary
| PPGNZ fundamental statistics | |
|---|---|
| Market cap | CHF 953.23m |
| Earnings (TTM) | -CHF 26.87m |
| Revenue (TTM) | CHF 304.39m |
3.1x
P/S Ratio-35.5x
P/E RatioIs PPGNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PPGNZ income statement (TTM) | |
|---|---|
| Revenue | €323.58m |
| Cost of Revenue | €306.38m |
| Gross Profit | €17.20m |
| Other Expenses | €45.76m |
| Earnings | -€28.56m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 11, 2025
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 5.32% |
| Net Profit Margin | -8.83% |
| Debt/Equity Ratio | 25.5% |
How did PPGNZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 06:29 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PolyPeptide Group AG is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Markus Mayer | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Konstantin Wiechert | Baader Helvea Equity Research |